Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
Open Access
- 30 September 2003
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 89 (7), 1172-1179
- https://doi.org/10.1038/sj.bjc.6601268
Abstract
In this Phase I/II trial, the patient's peripheral blood dendritic cells were pulsed with an autologous tumour lysate of the glioma. Seven patients with glioblastoma and three patients with anaplastic glioma, ranging in age from 20 to 69 years, participated in this study. The mean numbers of vaccinations of tumour lysate-pulsed dendritic cells were 3.7 times intradermally close to a cervical lymph node, and 3.2 times intratumorally via an Ommaya reservoir. The percentage of CD56-positive cells in the peripheral blood lymphocytes increased after immunisation. There were two minor responses and four no-change cases evaluated by radiological findings. Dendritic cell vaccination elicited T-cell-mediated antitumour activity, as evaluated by the ELISPOT assay after vaccination in two of five tested patients. Three patients showed delayed-type hypersensitivity reactivity to the autologous tumour lysate, two of these had a minor clinical response, and two had an increased ELISPOT result. Intratumoral CD4+ and CD8+ T-cell infiltration was detected in two patients who underwent reoperation after vaccination. This study demonstrated the safety and antitumour effects of autologous tumour lysate-pulsed dendritic cell therapy for patients with malignant glioma.Keywords
This publication has 34 references indexed in Scilit:
- 7-Hydroxystaurosporine-induced Apoptosis in 9L Glioma Cells Provides an Effective Antigen Source for Dendritic Cells and Yields a Potent Vaccine Strategy in an Intracranial Glioma ModelNeurosurgery, 2002
- Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki Forest virus—mediated complementary DNAJournal of Neurosurgery, 2001
- Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I–matched tumor peptidesNeurosurgical Focus, 2000
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigensJournal of Neurosurgery, 1999
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cellsNature Medicine, 1996
- T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in cultureBrain Research, 1995
- Production of IL‐10 by melanoma cells: Examination of its role in immunosuppression mediated by melanomaInternational Journal of Cancer, 1994
- Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo.The Journal of Experimental Medicine, 1993